Menin Inhibitor Landscape in NPM1-Mutated and KMT2A-Rearranged AML

The moderator opens the program, the panelists introduce themselves, and the moderator frames menin inhibition as a class that has moved from a first-in-class approval to 2 approved agents with guideline recognition and an evidence base that now reaches into the frontline and post-transplant settings. One panelist sets the stage on menin inhibition, including the biology behind it, and why NPM1-mutated and KMT2A-rearranged leukemias are subtypes that respond. The moderator reviews the approved indications for revumenib and ziftomenib, and the second panelist describes what that landscape looks like for community practices, starting with testing at relapse and then choosing between the agents. The segment closes on the menin inhibitors still in trials and the frontline combinations under study, and on individualizing the choice between approved monotherapy and a clinical trial.